NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report published on Sunday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Down 0.8 %

NURO stock opened at $3.92 on Friday. The company’s 50-day moving average price is $4.05 and its 200 day moving average price is $3.84. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73. The company has a market cap of $8.01 million, a P/E ratio of -0.85 and a beta of 2.18.

NeuroMetrix (NASDAQ:NURO) last released its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. The firm had revenue of $0.59 million for the quarter. During the same period in the previous year, the business earned ($1.66) earnings per share.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.